A new publication involving pasireotide was listed on October 1, 2026. The paper, titled "Predictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors," appeared in the Journal of Neuroendocrinology.
The publication addresses somatostatin and dopamine receptor-targeted treatments in the context of clinically non-functioning pituitary tumors. Pasireotide is a somatostatin receptor ligand, and its inclusion in this research relates to that treatment class.
No findings, results, or conclusions from the study are detailed in the available event data. The publication record confirms only the title, journal, and listing date as provided.
Readers interested in the broader context of pasireotide, including its approved regulatory status, can consult the compound overview for additional background.